BioLineRx Ltd.

1.76+0.0600+3.53%Vol 125.77K1Y Perf -44.08%
Aug 11th, 2022 16:00 DELAYED
BID1.73 ASK1.80
Open1.68 Previous Close1.70
Pre-Market- After-Market1.79
 - -  0.03 1.70%
Target Price
11.08 
Analyst Rating
Strong Buy 1.00
Potential %
529.55 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
35.05 
Earnings Rating
Strong Buy
Market Cap84.28M 
Earnings Date
17th Aug 2022
Alpha-0.04 Standard Deviation0.18
Beta2.00 

Today's Price Range

1.681.79

52W Range

1.013.15

5 Year PE Ratio Range

-2.90-1.40

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.15%
1 Month
27.54%
3 Months
62.96%
6 Months
2.92%
1 Year
-44.08%
3 Years
-42.11%
5 Years
-89.97%
10 Years
-95.43%

TickerPriceChg.Chg.%
BLRX1.760.06003.53
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.15-0.1033.33
Q04 2021-0.14-0.0842.86
Q03 2021-0.13-0.23-76.92
Q02 2021-0.12-0.15-25.00
Q01 2021-0.15-0.27-80.00
Q04 2020-0.25-0.61-144.00
Q03 2020-0.36-0.3016.67
Q02 2020-0.60-0.4525.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1412.50Positive
9/2022 QR-0.150.00-
12/2022 FY-0.518.93Positive
12/2023 FY-0.53-15.22Negative
Next Report Date17th Aug 2022
Estimated EPS Next Report-0.14
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume125.77K
Shares Outstanding47.89K
Shares Float47.89M
Trades Count343
Dollar Volume220.03K
Avg. Volume141.15K
Avg. Weekly Volume192.20K
Avg. Monthly Volume101.50K
Avg. Quarterly Volume129.75K

BioLineRx Ltd. (NASDAQ: BLRX) stock closed at 1.76 per share at the end of the most recent trading day (a 3.53% change compared to the prior day closing price) with a volume of 125.77K shares and market capitalization of 84.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. BioLineRx Ltd. CEO is Philip Serlin.

The one-year performance of BioLineRx Ltd. stock is -44.08%, while year-to-date (YTD) performance is -13.73%. BLRX stock has a five-year performance of -89.97%. Its 52-week range is between 1.01 and 3.1499, which gives BLRX stock a 52-week price range ratio of 35.05%

BioLineRx Ltd. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.05, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.35%, a ROC of -30.92% and a ROE of -35.02%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioLineRx Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. BioLineRx Ltd.’s next earnings report date is 17th Aug 2022.

The consensus rating of Wall Street analysts for BioLineRx Ltd. is Strong Buy (1), with a target price of $11.08, which is +529.55% compared to the current price. The earnings rating for BioLineRx Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioLineRx Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioLineRx Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.59, ATR14 : 0.11, CCI20 : 132.91, Chaikin Money Flow : 0.14, MACD : 0.10, Money Flow Index : 79.19, ROC : 36.43, RSI : 78.19, STOCH (14,3) : 94.01, STOCH RSI : 0.65, UO : 62.76, Williams %R : -5.99), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioLineRx Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioLineRx Ltd.

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.

CEO: Philip Serlin

Telephone: +972 86429100

Address: 2 HaMa'ayan Street, Modi'in 7177871, , IL

Number of employees: 38

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

60%40%

TipRanks News for BLRX

Thu, 12 May 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Biolinerx (BLRX), Steris (STE) and TRACON Pharmaceuticals (TCON)

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 16:40 GMT Biolinerx (BLRX) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits